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What is already known about this subject {#bcp13896-sec-0005}
========================================

Sickle cell disease affects millions of people worldwide and treatment remains a serious unmet need.Current approved treatments for sickle cell disease do not target the underlying pathophysiology of the disease.Haemoglobin oxygen affinity modulation to inhibit HbS polymerization is a promising and potentially disease‐modifying strategy for treating SCD.

What this study adds {#bcp13896-sec-0006}
====================

Once‐daily dosing with voxelotor increases Hb oxygen affinity into a range that may be therapeutic for SCD patients.Voxelotor once‐daily oral dosing demonstrated linear pharmacokinetics with dose‐dependent increases in haemoglobin‐oxygen affinity.Voxelotor was well tolerated with no dose‐limiting toxicities or indications of tissue hypoxia.

1. INTRODUCTION {#bcp13896-sec-0007}
===============

Sickle cell disease (SCD) is an autosomal recessive disorder caused by a mutation in the β‐chain of [haemoglobin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5370) (Hb) that leads to production of sickle haemoglobin (HbS).[1](#bcp13896-bib-0001){ref-type="ref"} When deoxygenated, HbS polymerizes and deforms red blood cells (RBCs) into a sickle shape, leading to permanent cell membrane damage,[1](#bcp13896-bib-0001){ref-type="ref"}, [2](#bcp13896-bib-0002){ref-type="ref"}, [3](#bcp13896-bib-0003){ref-type="ref"} painful vaso‐occlusive crisis, end‐organ damage and dysfunction, and early death.[1](#bcp13896-bib-0001){ref-type="ref"}, [3](#bcp13896-bib-0003){ref-type="ref"} SCD affects approximately 100 000 people in the United States and millions worldwide.[4](#bcp13896-bib-0004){ref-type="ref"}, [5](#bcp13896-bib-0005){ref-type="ref"} Current approved treatments for SCD include [hydroxyurea](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6822) [6](#bcp13896-bib-0006){ref-type="ref"} and [L‐glutamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=723).[7](#bcp13896-bib-0007){ref-type="ref"} To date, no drugs have been approved that target the underlying mechanism of SCD. Hydroxyurea is not effective in some patients and has significant safety concerns, including potential embryofetal toxicity and myelosuppression. L‐glutamine, recently approved, demonstrated only a modest effect in prevention of vaso‐occlusive crisis without improvement in haematologic parameters, and does not target the pathophysiologic mechanism of disease.[8](#bcp13896-bib-0008){ref-type="ref"}, [9](#bcp13896-bib-0009){ref-type="ref"} Therefore, a chronic preventive treatment remains a serious unmet need.

Because oxygenated Hb is a potent inhibitor of HbS polymerization, increasing the proportion of oxygenated HbS may provide a disease‐modifying approach to SCD.[10](#bcp13896-bib-0010){ref-type="ref"}, [11](#bcp13896-bib-0011){ref-type="ref"}, [12](#bcp13896-bib-0012){ref-type="ref"} Previous Hb allosteric modifiers such as 5‐hydroxymethylfurfural (5‐HMF),[13](#bcp13896-bib-0013){ref-type="ref"} tucaresol,[14](#bcp13896-bib-0014){ref-type="ref"}, [15](#bcp13896-bib-0015){ref-type="ref"} and valerosol (BW12C)[16](#bcp13896-bib-0016){ref-type="ref"} have been investigated. These agents (tucaresol and valerosol) demonstrated that increasing the Hb‐oxygen affinity at 20--30% Hb modification inhibited RBC sickling *in vitro* and reduced haemolysis in SCD patients without compromising oxygen delivery to tissues.[17](#bcp13896-bib-0017){ref-type="ref"}, [18](#bcp13896-bib-0018){ref-type="ref"} However, poor pharmaceutical properties (5‐HMF),[17](#bcp13896-bib-0017){ref-type="ref"} lack of specificity, and immunogenicity (tucaresol[18](#bcp13896-bib-0018){ref-type="ref"}) prevented further development. Because a positive pharmacodynamic (PD) effect was observed with 20--30% Hb modification, this target modification is expected to provide therapeutic effect. This also aligns with studies in individuals with compound heterozygosity for HbS and pancellular hereditary persistence of fetal Hb, where 20--30% pancellular fetal Hb conferred significant clinical benefits.[19](#bcp13896-bib-0019){ref-type="ref"}

Voxelotor (previously GBT440) is a first‐in‐class oral therapy developed for the treatment of SCD by modulating the Hb affinity for oxygen. Voxelotor forms a reversible covalent bond with the N‐terminal valine of the α‐chain of Hb, resulting in an allosteric modification of Hb[20](#bcp13896-bib-0020){ref-type="ref"} and eliciting an increase in oxygen affinity.[21](#bcp13896-bib-0021){ref-type="ref"} Because oxygenated HbS does not polymerize, voxelotor may prevent sickling of RBCs and potentially interrupt the molecular pathogenesis of the disease.

Following promising preclinical data, an "umbrella protocol" (GBT440‐001, NCT02285088) for a phase 1/2 study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), PD, PK‐PD relationship, and effect of voxelotor on cardiovascular parameters at rest and during exercise following single and multiple doses of voxelotor administered to healthy volunteers and SCD patients. Dose selection and dose escalation were pharmacologically guided based on analysis of PD effect among cohorts.

Here, we report results of single and multiple doses of voxelotor in healthy volunteers and a single dose in SCD patients. Results of multiple dosing in SCD patients are published elsewhere.[22](#bcp13896-bib-0022){ref-type="ref"}

2. METHODS {#bcp13896-sec-0008}
==========

GBT440‐001 was an integrated phase 1/2, two‐centre, randomized, double‐blind, placebo‐controlled, three‐part study of voxelotor in healthy volunteers and SCD patients. Part A, a single ascending dose (SAD) design, and part B, a multiple ascending dose (MAD) design, included both healthy volunteers and SCD patients. Part C included only SCD patients. The study was conducted in accordance with Good Clinical Practice guidelines and in conformity with the ethical principles of the Declaration of Helsinki and was compliant with all relevant country‐specific laws and regulations. The study protocol and all other appropriate study‐related information were reviewed and approved by an independent ethics committee.

2.1. Subjects {#bcp13896-sec-0009}
-------------

Healthy volunteers aged 18--55 years weighing between 50 kg and 110 kg at screening and SCD patients (HbSS, HbS/β^0^ thalassemia, HbS/β^+^ thalassemia or HbSC) aged 18--60 years weighing \>50 kg were included. For SCD patients, Hb genotype was confirmed at screening, and concurrent use of hydroxyurea was allowed if dose was stable for 3 months before entry. Key exclusion criteria for the healthy volunteers included the use of prescription drugs within 4 weeks of first dosing or the use of over‐the‐counter medications (excluding routine vitamins) within 7 days of first dosing. Key exclusion criteria for SCD patients included Hb levels \<60 g L^−1^ or \>104 g L^−1^ or transfusion or hospitalization within 30 days of screening. Full details of the inclusion and exclusion criteria for healthy volunteers and SCD patients are provided in [Table S1](#bcp13896-supitem-0001){ref-type="supplementary-material"}. All subjects provided written informed consent before the commencement of any study‐related procedures.

2.2. Study design and treatment {#bcp13896-sec-0010}
-------------------------------

An objective of this study was to demonstrate drug safety at high target percent Hb modification of \~40% (RBC concentration of 675 μg mL^−1^ or 2 mM) in healthy volunteers, the level at which there was evidence of a compensatory increase in cardiac output with exercise from prior studies with other agents with similar mechanisms.[15](#bcp13896-bib-0015){ref-type="ref"} To dose‐escalate safely and effectively, a pharmacologically guided approach was implemented (Figure [1](#bcp13896-fig-0001){ref-type="fig"}). The initial dose of 100 mg was selected based on allometric scaling of animal data to human to provide approximate 15‐fold margin below no‐observed‐adverse‐effect level of a 28‐day rat toxicology study and to be below the anticipated pharmacologically active dose (≤5% Hb modification). Following the initial dose of 100 mg, subsequent doses of voxelotor were administered to target 5%, 10%, 20% and 30% Hb modification. The first MAD dose (300 mg) was initiated as soon as safety was demonstrated in the single dose subjects at \~20% Hb modification (2000 mg). The final MAD dose was targeted at 40% Hb modification. The multiple dose study in SCD patients was initiated following demonstration of safety in healthy volunteers at equivalent percent Hb modification.

![Study design and dose‐escalation scheme. Stepwise dose‐escalation scheme for healthy volunteers and SCD patients. In each cohort, eight subjects were randomized to receive voxelotor (*n* = 6) or placebo (*n* = 2). Following the first dose, subsequent doses were escalated to reach 5%, 10% and 20% Hb modification. The first MAD cohort started after equivalent Hb modification was achieved in the single‐dose cohort. The maximum target for the MAD cohort was 40% Hb modification. Food effect was evaluated at 400 mg. Single dose in SCD subjects was initiated at 1000 mg, and the data were used to estimate MAD doses at targeted 20% and 30% Hb modification](BCP-85-1290-g001){#bcp13896-fig-0001}

2.3. Safety {#bcp13896-sec-0011}
-----------

Safety and tolerability were monitored at regular intervals from predose to a follow‐up visit (27 days following completion of single doses and 45 days following completion of multiple doses). Safety assessments included physical examinations, vital signs, electrocardiograms, clinical laboratory assessments, incidence of clinical adverse events and concomitant medications. Any clinically significant abnormal laboratory test results were followed until resolved or stabilized. No formal power calculations were performed. The sample size was based on the desire to obtain adequate safety, tolerability, PK and PD data to achieve the objectives of the study whilst exposing as few subjects as possible to study medication and procedures.

### 2.3.1. Part A: SAD {#bcp13896-sec-0012}

In each dose cohort, healthy volunteers were randomized to voxelotor (*n* = 6) or placebo (*n* = 2). Two sentinel subjects per cohort were dosed (one randomized to voxelotor and one randomized to placebo). Providing there were no serious or unexplained safety issues, the remainder of the cohort were dosed 48 h later. A minimum of 10 days was allowed between the last dose administered in one cohort and the first dose administered in the next cohort. The starting dose was 100 mg, and subsequent dose escalations for healthy volunteer cohorts were 400, 1000, 2000 and 2800 mg. Six SCD patients were administered a single dose of 1000 mg voxelotor and two patients received placebo following completion of the 1000 mg cohort in healthy volunteers. Voxelotor or placebo was administered orally with at least 240 mL water, after an overnight fast of approximately 8--10 h.

The effect of food on PK and PD was assessed in a nonrandomized, crossover design in the cohort of healthy volunteers who received 400 mg voxelotor. Subjects returned to the study centre after a washout period (minimum of 28 days after the first dose of study medication) to receive a second single dose of the same treatment (400 mg voxelotor or placebo) 30 min after the start of a low‐fat breakfast.

### 2.3.2. Part B: MAD {#bcp13896-sec-0013}

Healthy volunteers in all cohorts were randomized 3:1 to voxelotor or placebo. Three cohorts were enrolled to receive 15 days of treatment with voxelotor doses of 300, 600 and 900 mg once daily or matching placebo. Cohorts were dosed sequentially, with a minimum of 10 days between the last dose of the one cohort and the first dose of the next cohort.

2.4. Pharmacokinetics {#bcp13896-sec-0014}
---------------------

Serial blood samples were obtained for PK analyses for the determination of voxelotor concentrations in whole blood, plasma and RBCs. Samples were analysed using a validated liquid chromatography--tandem mass spectrometry method. Analytical ranges were 10--10 000 ng mL^−1^ and 5--5000 ng mL^−1^ for blood and plasma samples, respectively. Percent coefficients of variation (%CV) for lower limit of quantitation for intra‐ and inter‐run was \<11.8% for the whole blood method and \<6.9% for the plasma method. Concentration of voxelotor in RBC was calculated from[23](#bcp13896-bib-0023){ref-type="ref"}: $$\mathit{RBC}\ \textit{Conc} = \frac{\textit{Blood\ Conc} - \left\lbrack {\left( {1 - \textit{Hematocrit}} \right)*\textit{Plasma\ Conc}} \right\rbrack}{\textit{Hematocrit}}$$

2.5. Pharmacodynamics {#bcp13896-sec-0015}
---------------------

Percent Hb modification was determined by measuring the oxygen equilibrium curves (OECs) and changes in Hb‐oxygen affinity using a TCS Hemox Analyzer. Clinical samples collected in sodium citrate vacutainers were kept at 4°C and analysed according to the method previously described[21](#bcp13896-bib-0021){ref-type="ref"} to obtain p20 and p50 values (partial pressure of O~2~ at which Hb is 20% or 50% saturated with O~2~). Delta p20 (∆ p20) and delta p50 (∆ p50) values were obtained by subtracting the day −1 from the sample value.

2.6. Haematology and serum erythropoietin {#bcp13896-sec-0016}
-----------------------------------------

Erythrocyte, reticulocyte, white blood cell and platelet counts were determined with a Siemens Advia 2120i (Siemens Healthcare Diagnostics, Surrey, UK). Serum [erythropoietin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4921) (EPO) was measured by a chemiluminescent assay on a Siemens Immulite XPi (Siemens Healthcare Diagnostics, Surrey, UK).

2.7. Exercise testing {#bcp13896-sec-0017}
---------------------

Exercise testing was performed based on the Young Men\'s Christian Association submaximal cycle ergometer test protocol.[24](#bcp13896-bib-0024){ref-type="ref"} Heart rate, respiratory rate, blood pressure and pulse oximetry (oxygen saturation) were evaluated.

2.8. Statistical analysis {#bcp13896-sec-0018}
-------------------------

Demographic data were summarized by dose. PK, PD and safety data were summarized by dose and presented as summary statistics.

PK parameters, including maximum concentration (*C* ~max~), time to reach maximum concentration (*T* ~max~), area under the concentration--time curve extrapolated to infinity following a single dose (AUC~inf~) or over 24‐h dose interval at steady‐state for multiple dosing (AUC~0--24~) and elimination half‐life (*T* ~1/2~), were derived using noncompartmental methods with Phoenix^®^ WinNonlin^®^ Version 6.4 (Certara, Princeton, NJ, USA).

p20 and p50 values between doses were compared using Sidak\'s multiple comparisons tests to measure statistical significance. PK/PD correlations were determined using linear regression.

2.9. Nomenclature of targets and ligands {#bcp13896-sec-0019}
----------------------------------------

Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY,[25](#bcp13896-bib-0025){ref-type="ref"} and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18.[26](#bcp13896-bib-0026){ref-type="ref"}

3. RESULTS {#bcp13896-sec-0020}
==========

3.1. Demographics and baseline characteristics {#bcp13896-sec-0021}
----------------------------------------------

A total of 40 healthy volunteers were randomized to receive a single dose of voxelotor (100, 400, 1000, 2000 or 2800 mg; *n* = 6 per group) or placebo (*n* = 2 per group). Six SCD patients received 1000 mg voxelotor and two received placebo. A total of 24 healthy volunteers were randomized to receive multiple doses of voxelotor (300, 600 or 900 mg; *n* = 6 per group) or placebo (*n* = 2 per group; total *n* = 8). The demographics for these subjects are summarized in Table [1](#bcp13896-tbl-0001){ref-type="table"}. Mean age and body mass index were similar across the dosing groups. There was no apparent impact of race on any PK or PD parameters of voxelotor.

###### 

Patient baseline and demographic data

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Part                     A\                      A Sickle cell disease Single dose   B Healthy volunteers Multiple ascending dose                                                                                                                                                                 
                           Healthy volunteers\                                                                                                                                                                                                                                                      
                           Single ascending dose                                                                                                                                                                                                                                                    
  ------------------------ ----------------------- ----------------------------------- ---------------------------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ----------------- -------------------
  *n*                      10                      6                                   6                                              6                   6                   6                   2                   6                   6                   6                   6                 6

  Age, median (range), y   34 (22--44)             33 (19--50)                         33 (24--40)                                    33 (27--43)         36 (27--48)         35 (28--51)         27 (20--34)         31 (25--47)         34 (22--48)         30 (23--54)         38 (23--49)       40 (27--54)

  Male sex, n (%)          10 (100)                6 (100)                             6 (100)                                        6 (100)             5 (83.3)            6 (100)             1 (50)              3 (50)              6 (100)             6 (100)             6 (100)           6 (100)

  Race, n (%)                                                                                                                                                                                                                                                                                       

  Asian                    0                       1 (16.7)                            0                                              2 (33.3)            0                   1 (16.7)            0                   0                   1 (16.7)            0                   0                 2 (33.3)

  Black                    1 (10%)                 0                                   1 (16.7)                                       1 (16.7)            0                   2 (33.3)            2                   6                   0                   1 (16.7)            0                 0

  White                    9 (90%)                 3 (50)                              4 (66.7)                                       3 (50)              6                   2 (33.3)            0                   0                   5 (83.3)            5 (83.3)            6 (100)           4 (66.7)

  Other                    0                       2 (33.3)                            1 (16.7)                                       0                   0                   1 (16.7)            0                   0                   0                   0                   0                 0

  BMI median (range)       24.7 (22.4--28.1)       25.7 (24.4--28.5)                   25.3 (21.7--26.8)                              24.7 (22.4--28.3)   25.1 (22.1--28.2)   28.5 (19.7--35.3)   25.8 (25.3--26.2)   21.9 (20.2--23.9)   26.5 (22.4--27.5)   26.5 (22.6--29.5)   24.9 (20.4--30)   26.1 (23.2--30.7)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI, body mass index.

3.2. Safety and tolerability {#bcp13896-sec-0022}
----------------------------

Following single doses, voxelotor was well tolerated up to and including the highest dose evaluated (2800 mg); i.e., a maximum tolerated single dose was not determined. Five treatment‐emergent adverse events (TEAEs; diarrhoea, upper respiratory tract infection, arthralgia, headache and rash) were reported in \>1 healthy volunteer (Table [2](#bcp13896-tbl-0002){ref-type="table"}). Of these, diarrhoea and headache were considered related to study drug. Diarrhoea occurred only at 2800 mg. In SCD patients receiving a single dose of 1000 mg voxelotor, four TEAEs (diarrhoea, nausea, vomiting and pain) were reported in \>1 SCD patient (Table [3](#bcp13896-tbl-0003){ref-type="table"}). Of these, diarrhoea, nausea and vomiting were considered related to study drug. All AEs reported following a single dose of voxelotor in healthy volunteers and SCD patients were grade 1 (mild).

###### 

TEAEs occurring in \>1 healthy volunteer receiving a single dose of voxelotor or placebo

  Single ascending dose in healthy volunteers                           
  --------------------------------------------- --- --- --- --- --- --- ---
  Diarrhoea                                                     3   3   
  Upper respiratory tract infection                     1   1       2   1
  Arthralgia                                        1   1           2   
  Headache                                          1       1       2   1
  Rash (all types)                              1       1           2   1

All AEs were grade 1.

###### 

TEAEs occurring in \>1 SCD patient receiving a single dose of voxelotor or placebo

              Patients with SCD (1000 mg)   Placebo
  ----------- ----------------------------- ---------
  Diarrhoea   3                             0
  Nausea      2                             0
  Vomiting    2                             0

All AEs were grade 1.

Following multiple doses, voxelotor was well tolerated up to and including the highest dose evaluated (900 mg daily for 15 days); i.e., a maximum tolerated multiple dose was not determined. Five TEAEs (abdominal pain, diarrhoea, gastroenteritis, dizziness and headache) were reported in ≥10% of healthy volunteers (Table [4](#bcp13896-tbl-0004){ref-type="table"}). Headache, diarrhoea and abdominal pain were considered related to study drug. Most AEs were grade 1 in subjects receiving voxelotor; all AEs were grade 1 in subjects receiving placebo. Three subjects who received voxelotor experienced grade 2 (moderate) events: one at 300 mg and two at 900 mg. No dose‐limiting toxicities were identified. Two subjects discontinued study drug because of TEAEs; one subject receiving 600 mg discontinued on Day 12 because of a grade 1 rash and one subject receiving 900 mg discontinued on Day 7 because of a grade 2 headache along with grade 1 diarrhoea and abdominal pain. The rash was a typical and uncomplicated maculopapular rash. These events resolved without treatment except for headache, which was treated with [paracetamol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5239).

###### 

TEAEs occurring in \>1 healthy volunteer receiving 15 days of voxelotor or placebo

  -----------------------------------------------------------------------------------------------------------------------------------------------
                    Voxelotor                                         Placebo\                                                                
                                                                      *n* = 6                                                                 
  ----------------- ------------------------------------------------- ---------- ------------------------------------------------- ---------- ---
  Abdominal pain    0                                                 0          2 (33.3)                                          2 (11.1)   0

  Diarrhoea         0                                                 0          3 (50.0)                                          3 (16.7)   0

  Gastroenteritis   1 (16.7)[a](#bcp13896-note-0004){ref-type="fn"}   0          1 (16.7)[a](#bcp13896-note-0004){ref-type="fn"}   2 (11.1)   0

  Dizziness         2 (33.3)                                          0          0                                                 2 (11.1)   0

  Headache          1 (16.7)[a](#bcp13896-note-0004){ref-type="fn"}   0          4 (66.7)[a](#bcp13896-note-0004){ref-type="fn"}   5 (27.8)   0
  -----------------------------------------------------------------------------------------------------------------------------------------------

All AEs were grade 1 except for grade 2 gastroenteritis and grade 2 headache (2 of 4 events, grade 2).

A theoretical concern with Hb‐oxygen affinity modifiers is that they could reduce tissue oxygen delivery per unit volume of blood, resulting in a compensatory increase in EPO with subsequent reticulocytosis, increased RBC mass and increased cardiac output under conditions of exercise stress.[18](#bcp13896-bib-0018){ref-type="ref"}, [27](#bcp13896-bib-0027){ref-type="ref"} To evaluate this concern, several specific assessments were performed including evaluation of reticulocyte counts, EPO levels and haemodynamic response to submaximal exercise testing. After multiple doses in healthy volunteers up to 900 mg daily, which achieved approximately 40% Hb modification, there was no evidence of a treatment‐related increase in reticulocyte count or Hb level, EPO remained in the normal range (Figure [2](#bcp13896-fig-0002){ref-type="fig"}), and there was no increase in resting or peak exercise heart rate (data not shown).

![Hb, reticulocyte count, and EPO levels following 900 mg voxelotor once daily for 15 days in healthy volunteers. Hb, reticulocyte count, and EPO values in healthy volunteers at predose, Day 15, and follow‐up (\~45 days after the last dose). Data are shown as mean ± standard deviation](BCP-85-1290-g002){#bcp13896-fig-0002}

3.3. Pharmacokinetics {#bcp13896-sec-0023}
---------------------

RBC and plasma concentration--time profiles of voxelotor following single dose (100--2800 mg) and multiple doses (300--900 mg), Day 15, in healthy volunteers are presented in Figure [3](#bcp13896-fig-0003){ref-type="fig"}. Comparison of RBC concentration--time profiles between healthy volunteers and SCD patients following 1000 mg are shown in Figure [4](#bcp13896-fig-0004){ref-type="fig"}. PK parameters are summarized in Table [5](#bcp13896-tbl-0005){ref-type="table"}. Following single dose administration to healthy volunteers, voxelotor was rapidly absorbed into the plasma with median *T* ~max~ \< 4 h at doses \<2000 mg. At 2800 mg, *T* ~max~ occurred later (7 h), likely because of continuing absorption of high drug load. Later *T* ~max~ was observed in RBC (17--24 h). *C* ~max~ and AUC of RBC and plasma increased proportionally with voxelotor dose for single or multiple doses. The exposure of voxelotor at steady‐state accumulated as predicted based on the single‐dose data. Following a daily dose of voxelotor at 300, 600 and 900 mg for 15 days, at steady state, the respective mean RBC *C* ~max~ were 225, 462 and 688 μg mL^−1^ and RBC AUC~(0--24)~ were 4950, 9610 and 14 000 μg\*h mL^−1^. The accumulation was approximately six‐fold from that of Day 1 exposure. *T* ~1/2~ of voxelotor ranged from 61 to 85 h. Plasma concentration declined in parallel to RBC concentration. Voxelotor had high specific binding to RBC as evidenced by the RBC/plasma ratio ranging from 67:1 to 111:1. Inter‐subject variability for *C* ~max~ and AUC values was low at doses ≤1000 mg for both single (%CV ≤ 22%) and multiple dosing at steady‐state (%CV ≤ 15%). However, at 2000 and 2800 mg, the %CV for *C* ~max~ was 22--36% and for AUC was approximately 28% for both doses. The higher inter‐subject variability at 2000 and 2800 mg was likely caused by variability in dissolution of voxelotor in the gut of individual subjects at high drug loads due to its low solubility (\~43 μg mL^−1^ in simulated intestinal fluid). At the same 1000 mg single dose, inter‐subject variability for *C* ~max~ and AUC of SCD patients (30--33%) was higher than that in healthy volunteers (10--17%), possibly due to the higher variability in the hematocrit values (0.20--0.28) of SCD patients compared to healthy volunteers (0.40--0.45).

![RBC and plasma voxelotor concentration--time profiles after single and multiple doses in healthy volunteers. Healthy volunteers (*n* = 6/cohort) received single dose of voxelotor at 100, 400, 1000, 2000 and 2800 mg. Concentration--time profiles in RBC (A) and plasma (B) show linear increase in exposure across these doses. Following daily dose at 300, 600 and 900 mg voxelotor for 15 days, RBC (C) and plasma (D) profiles on Day 15 also proportionally increase. Data are shown as mean ± standard deviation](BCP-85-1290-g003){#bcp13896-fig-0003}

![RBC concentration--time profiles of voxelotor following 1000‐mg single dose in healthy volunteers and SCD patients. RBC concentration--time profiles in healthy volunteers (*n* = 6) and SCD patients (*n* = 6) receiving 1000 mg voxelotor single dose. Similar *C* ~max~ was achieved but AUC~inf~ in healthy volunteers was higher than in SCD patients because of longer *T* ~1/2~. Data are shown as mean ± standard deviation](BCP-85-1290-g004){#bcp13896-fig-0004}

###### 

RBC and plasma voxelotor PK parameters in healthy volunteers and SCD patients

                                                                  Single dose         Multiple doses                                                                                                                    
  ---------------------------------------------------------- ---------------------- ------------------ ------------------ ------------------- ------------------ ------------------ ----------------- ----------------- ----------------
  Dose, mg                                                            100                  400                1000               2000                2800               1000               300               600              900
                                                               RBC PK parameters                                                                                                                                        
  *T* ~max~, h                                                 18.0 (12.0--24.1)     24.0 (8.0--24.1)   18.0 (8.0--24.0)   16.6 (12.6--25.0)   17.1 (9.0--25.2)   14.0 (6.0--25.6)   6.0 (1.0--12.0)   8.0 (6.0--20.0)   8.0 (2.0--8.0)
  *C* ~max~, μg mL^−1^                                            13.8 ± 3.48          77.3 ± 31.4         136 ± 16.1         222 ± 67.5          377 ± 137          146 ± 46.6        225 ± 29.1        462 ± 59.8        688 ± 25.7
  AUC[a](#bcp13896-note-0006){ref-type="fn"}, μg\*h mL^−1^         1540 ± 343           8080 ± 902       15 800 ± 2430       24 200 ± 5860     38 800 ± 13 400     10 000 ± 2860       4950 ± 520        9610 ± 1000      14 000 ± 612
  *T* ~1/2~, h                                                    64.7 ± 2.60          68.6 ± 5.61        61.1 ± 7.30         63.6 ± 6.64        63.6 ± 11.0        49.7 ± 2.87        80.3 ± 1.89       76.5 ± 3.79      85.1 ± 7.43
  RAUC~(0--24h)~                                                       --                   --                 --                 --                  --                 --           6.09 ± 0.687       6.16 ± 1.91      6.42 ± 1.05
                                                              Plasma PK parameters                                                                                                                                      
  *T* ~max~, h                                                   2.0 (1.0--2.0)       2.0 (1.0--8.0)     4.0 (2.0--6.0)     2.5 (2.5--8.5)      7.1 (3.1--9.1)     2.0 (1.3--2.2)    4.0 (1.0--12.0)   6.0 (1.0--6.0)    2.0 (1.0--8.0)
  C~max~, μg mL^−1^                                              0.269 ± 0.0819        1.14 ± 0.502       2.21 ± 0.388       3.39 ± 0.731        6.31 ± 2.29        2.94 ± 0.747      2.91 ± 0.410      5.78 ± 0.834      11.4 ± 1.70
  AUC[a](#bcp13896-note-0006){ref-type="fn"}, μg\*h mL^−1^        14.8 ± 3.20          74.5 ± 16.8         166 ± 17.1         266 ± 74.5          433 ± 121          134 ± 27.3        56.6 ± 8.70       113 ± 13.2        215 ± 32.7
  RBC/plasma ratio                                                 104 ± 14.9           111 ± 17.6        95.3 ± 9.00         92.0 ± 8.86        87.9 ± 7.44        75.0 ± 15.7        88.0 ± 4.85       85.0 ± 4.77      66.6 ± 11.1

Data are presented as mean ± standard deviation for *C* ~max~, AUC, *T* ~1/2~, RBC/plasma ratio, RAUC~(0--24h)~ or median (range) for *T* ~max~. For multiple dose, PK parameters on day 15 are presented.

AUC~inf~ value for single dose and AUC~(0--24h)~ value on Day 15 for multiple doses are shown.

Following single‐dose administration of 1000 mg to SCD patients, voxelotor was rapidly absorbed into the plasma with median *T* ~max~ of 2 h and *C* ~max~ of 2.9 μg mL^−1^. In RBCs, median *T* ~max~ of voxelotor was 14 h and *C* ~max~ was 146 μg mL^−1^. The AUC ratio in RBCs over plasma was 75:1. Terminal *T* ~1/2~ was 50 h. This long *T* ~1/2~ suggests suitability for once‐daily dosing.

The effect of food on the PK of voxelotor was evaluated by comparing exposure following a 400 mg single dose under fasted *vs*. fed (low‐fat breakfast) conditions. The absorption rate and exposure were similar under these two conditions. The *T* ~max~, *C* ~max~ and AUC~inf~ in RBCs under fasted conditions were 24 h, 77.3 μg mL^−1^ and 8080 μg\*h mL^−1^, respectively; and under fed conditions were 10 h, 74.4 μg mL^−1^ and 8690 μg\*h mL^−1^, respectively. Relative bioavailability of voxelotor under fed condition was 108% (90% confidence interval = 100.73%, 115.82%) compared with the fasted condition, indicating that a low‐fat breakfast had no significant effect on voxelotor exposure.

3.4. Pharmacodynamics {#bcp13896-sec-0024}
---------------------

Blood samples collected from volunteers at various timepoints during both SAD and MAD studies were used to determine changes in Hb‐oxygen affinity via OEC measurement. As the dose increased, both the p20 and p50 values decreased indicating an increase in Hb‐oxygen affinity (Table [6](#bcp13896-tbl-0006){ref-type="table"}). Figure [5](#bcp13896-fig-0005){ref-type="fig"}A shows representative OECs at 24 h for the three MAD cohorts following the dose on Day 15. Following daily dosing of placebo, 300, 600 and 900 mg voxelotor for 15 days, the mean p50s and p20s were 30.7, 29.9, 24.3 and 24.6 mm Hg and 16.2, 14.1, 9.4 and 6.3 mm Hg, respectively. A summary of the p20 and p50 changes observed at *C* ~min~ after 15 days of dosing is shown in Figures [5](#bcp13896-fig-0005){ref-type="fig"}B and [5](#bcp13896-fig-0005){ref-type="fig"}C. Due to the biphasic nature of the OECs generated by voxelotor, the changes in p20 value compared with Day −1 were more prominent and significant (Figure [5](#bcp13896-fig-0005){ref-type="fig"}B) than the changes in p50 value (Figure [5](#bcp13896-fig-0005){ref-type="fig"}C), especially at the lowest dose (300 mg) with voxelotor RBC concentrations \<0.75 mM (equivalent to \<15% Hb modification, Figures [5](#bcp13896-fig-0005){ref-type="fig"} and [7](#bcp13896-fig-0007){ref-type="fig"}D). Based on a previously established *in vitro* correlation (Figure [S1](#bcp13896-supitem-0001){ref-type="supplementary-material"}, Table [S2](#bcp13896-supitem-0001){ref-type="supplementary-material"}), percent Hb modification was calculated from the ∆p20 values and are summarized in Table [6](#bcp13896-tbl-0006){ref-type="table"}. The mean percent Hb modifications at 24 h following a single dose of 100, 400, 1000, 2000 and 2800 mg voxelotor were 1.4%, 3.4%, 5.9%, 7.9% and 23.6%, respectively. The mean percent Hb modifications following 300, 600 and 900 mg day^−1^ on Day 15 were 10.9%, 24.1% and 38.3%, respectively.

###### 

PD parameters in healthy volunteers and SCD patients

               A (healthy volunteers, single ascending dose)[a](#bcp13896-note-0008){ref-type="fn"}   A (SCD, single dose)   B (healthy volunteers, multiple ascending dose)[c](#bcp13896-note-0010){ref-type="fn"}                                                                                                                                               
  ------------ -------------------------------------------------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------- ------------ ------------ ------------ ------------------------------------------------ ------------ ------------ ------------ ------------ ------------
  Dose, mg     Placebo                                                                                100                    400                                                                                      1000         2000         2800         Placebo[b](#bcp13896-note-0009){ref-type="fn"}   1000         Placebo      300          600          900
  p50, mm Hg   30.1 ± 1.7                                                                             26.0 ± 1.7             30.5 ± 1.7                                                                               29.6 ± 1.0   28.2 ± 1.2   27.4 ± 2.0   37.1                                             33.5 ± 2.8   30.7 ± 2.2   29.9 ± 1.7   24.3 ± 1.5   24.6 ± 2.5
  p20, mm Hg   15.9 ± 1.1                                                                             12.7 ± 1.5             15.6 ± 0.9                                                                               14.5 ± 0.7   13.4 ± 0.8   10.0 ± 3.1   19.9                                             16.8 ± 2.6   16.2 ± 1.3   14.1 ± 1.0   9.4 ± 1.1    6.3 ± 0.8
  \% Hb mod    −0.3 ± 4.1                                                                             1.4 ± 1.4              3.4 ± 2.2                                                                                5.9 ± 4.4    7.9 ± 3.9    23.6 ± 8.6   −3.1                                             7.1 ± 10.8   −1.0 ± 4.8   10.9 ± 3.6   24.1 ± 2.4   38.3 ± 8.6

Data are presented as mean ± standard deviation.

Data from 24 h post dose.

*n* = 1; day −1 data were not usable.

Data from 24 h post final dose, *C* ~min~.

![PD at steady state in healthy volunteers. A, Selected median OECs from subjects at *C* ~min~ after 15 days of dosing. A summary of the p20 (B) and p50 (C) values observed in healthy volunteers at *C* ~min~ after 15 days of dosing. A dose--dependent decrease in p20 and p50 was observed, showing that increasing levels of drug leads to increased Hb‐oxygen affinities. Sidak\'s multiple comparisons tests were used to measure statistical significance](BCP-85-1290-g005){#bcp13896-fig-0005}

Following a single dose of 1000 mg voxelotor, SCD patients and healthy volunteers achieved similar maximum percentage Hb modification (Table [6](#bcp13896-tbl-0006){ref-type="table"}). In SCD, because of the anaemia, RBCs tend to have a higher 2,3‐bisphosphoglycerate concentration leading to a lower Hb‐oxygen affinity, and a rightward shifted OEC. Figure [6](#bcp13896-fig-0006){ref-type="fig"} shows the OEC for a predosed SCD patient, compared with the 24‐h OEC post 1000 mg voxelotor dose, which exhibits a leftward shifted OEC, trending towards the OEC of a healthy volunteer.

![Oxygen equilibrium curves from blood of a voxelotor‐treated SCD patient compared with a healthy volunteer. Representative predose and 24 h postdose OECs of SCD patients who achieved 23% Hb modification on a single 1000‐mg voxelotor dose, compared with the OEC of a healthy volunteer on placebo](BCP-85-1290-g006){#bcp13896-fig-0006}

3.5. PK/PD correlations {#bcp13896-sec-0025}
-----------------------

A percent Hb occupancy was calculated as the ratio of the voxelotor concentration to the Hb concentration (estimated at 5 mM) in RBCs. $$\%\mathit{Hb}\ \textit{occupancy} = 100*\left( \frac{\left\lbrack \textit{voxelotor} \right\rbrack_{\mathit{RBC}}}{5} \right)$$

Figure [7](#bcp13896-fig-0007){ref-type="fig"}A illustrates that the percent Hb modification (derived from OECs) is highly correlated (*R* ^2^ = 0.82) with the percent Hb occupancy (derived from the voxelotor concentration in RBCs). Figure [7](#bcp13896-fig-0007){ref-type="fig"}B shows the correlation between ∆p20 and RBC voxelotor concentrations in samples from healthy volunteers. These correlations allow for an estimation of the Hb‐oxygen affinity in future studies when only the RBC voxelotor levels are available. Figure [7](#bcp13896-fig-0007){ref-type="fig"}C shows a linear and robust correlation between p20 values and RBC levels of voxelotor (*R* ^2^ = 0.65). As expected, the correlation with p50 values is less robust (*R* ^2^ = 0.23) (Figure [7](#bcp13896-fig-0007){ref-type="fig"}D). However, when data from 0 to 15% Hb modification (derived from OECs) is omitted, the correlation is improved to *R* ^2^ = 0.45, indicating that correlations with p50 improve at higher percent Hb modifications.

![PK/PD correlation in healthy volunteers. A, Linear correlation observed between percent Hb modification derived from OECs and percent Hb occupancy (derived from \[voxelotor\]~RBC~) in healthy volunteers. B, Correlation observed between Δp20 and RBC voxelotor concentrations or percent Hb occupancy. C, Correlation observed between p20 and RBC voxelotor concentrations. D, Correlation observed between p50 and RBC voxelotor concentrations](BCP-85-1290-g007){#bcp13896-fig-0007}

4. DISCUSSION {#bcp13896-sec-0026}
=============

This is the first study of voxelotor in healthy volunteers and SCD patients to evaluate safety, tolerability, PK, PD and PK/PD relationship. Voxelotor was administered as a single dose at 100, 400, 1000, 2000 and 2800 mg and once daily for 15 days at 300, 600 and 900 mg to healthy volunteers. The dose increments were determined based on emerging tolerability, PK and PD data. PK and PD following a single dose of 1000 mg voxelotor in SCD patients was also reported. PK profiles in plasma and RBCs were monitored to demonstrate voxelotor binding specificity to Hb and concentrations in the target compartment (RBCs). Following oral administration to healthy volunteers, voxelotor was rapidly absorbed into plasma followed by distribution into RBCs as demonstrated by earlier plasma *T* ~max~ (2--4 h) than RBC *T* ~max~ (16--24 h). Nevertheless, the voxelotor concentration in RBCs reached near *C* ~max~ levels within an hour after administration and continued to increase slowly until the *C* ~max~ was reached. This observation supports previous *in vitro* data which show that voxelotor has a higher binding affinity for Hb than for plasma proteins.[28](#bcp13896-bib-0028){ref-type="ref"} These distribution profiles are consistent across animal species tested.[21](#bcp13896-bib-0021){ref-type="ref"} Voxelotor is mainly eliminated by metabolism in humans with \<1% of the dose administered excreted unchanged into urine.[29](#bcp13896-bib-0029){ref-type="ref"} The *T* ~1/2~ of voxelotor (\~60 days) is much shorter than the *T* ~1/2~ of human RBC,[30](#bcp13896-bib-0030){ref-type="ref"} implying its binding to Hb is a reversible process and drug can be released from Hb before being further metabolized.

In healthy volunteers, the PK of voxelotor was linear between 100 and 2800 mg. Accumulation of voxelotor was also linear upon multiple dosing. The unique PK properties of voxelotor are critical in binding to high abundance target and achieving the target Hb modification at a reasonable oral dose (e.g., 900 mg day^−1^ could achieve \~40% Hb modification in healthy volunteers). In addition, the high RBC to plasma partitioning results in relatively low plasma concentrations, thus reducing the risk of dose‐related off‐target toxicities. The high selectivity of voxelotor for Hb with a lack of off‐target safety concerns, together with pharmaceutical properties enabling once daily dosing, represent a significant advance over prior attempts at developing Hb‐modifying agents.[18](#bcp13896-bib-0018){ref-type="ref"}, [31](#bcp13896-bib-0031){ref-type="ref"}, [32](#bcp13896-bib-0032){ref-type="ref"} In SCD patients, voxelotor was also rapidly absorbed into plasma following oral administration, then distributed into RBCs. Although SCD patients achieved the same *C* ~max~ as healthy volunteers, the AUC and *T* ~1/2~ of voxelotor in SCD patients were lower than those observed in healthy volunteers. The mean *T* ~1/2~ of voxelotor was 50 h in SCD patients compared with 61--85 h in healthy volunteers. These differences are likely due to lower hematocrit and decreased RBC *T* ~1/2~ in SCD patients compared with healthy volunteers. As *C* ~max~ levels were similar between SCD patients and healthy volunteers, both exhibited similar percent Hb modifications, indicating the same potency of voxelotor in normal (AA) blood and sickle (SS) blood.

Consistent with the *in vitro* findings,[21](#bcp13896-bib-0021){ref-type="ref"} OECs of voxelotor in human subjects exhibited a biphasic profile because of the coexistence of Hb species with varying oxygen affinity. Voxelotor exhibited a concentration‐dependent decrease in p20 and p50 values following the various dosing regimens. The biphasic nature of OECs yields differentiable p20 values at clinical voxelotor concentration ranges, while p50 shift was not significant at low voxelotor concentrations but became more prominent at higher voxelotor concentration; i.e., \>0.75 mM (equivalent to \~15% Hb modification). In this study, the changes in p20 values at steady state compared with predose level were significant at all three dose levels, whereas p50 showed a shift at 600 and 900 mg but not at the 300 mg dose. Therefore, consistent with the previously established *in vitro* model, p20 is more suitable than p50 in assessing the pharmacologic activity of voxelotor at therapeutic doses and RBC concentrations.

There was a linear relationship between ∆p20 measured from samples in this clinical study and percent Hb occupancy. Percent Hb occupancy correlated with percent Hb modification. Therefore, percent Hb occupancy could be utilized as a determinant for the extent of Hb modification in future clinical studies when p20 values are not available.

Evaluation of EPO, exercise testing and haematologic parameters was consistent with maintenance of normal oxygen delivery during rest and exercise up to the exposures achieved in this study, indicating that the percent Hb modification achieved in this study did not impair the ability of Hb to deliver oxygen to tissues.

In this first‐in‐human study, the highest single dose studied in SCD patients (1000 mg) and healthy volunteers (2800 mg) was well tolerated, as was a 15‐day course of 900 mg once daily in healthy volunteers and established proof of mechanism on increasing Hb‐oxygen affinity. Voxelotor PK was linear and predictable across the dose range tested. The drug showed a high binding specificity for Hb, and demonstrated a long half‐life, allowing sustained PD effect with once‐daily dosing.
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**TABLE S1A** Inclusion and exclusion criteria for healthy volunteers

**TABLE S1B** Inclusion and exclusion criteria for patients with SCD

**TABLE S1C** Inclusion and exclusion criteria for all subjects

**TABLE S2** Models and model robustness across four potential parameters

**TABLE S3** Models and model robustness across four potential parameters in SS blood

**FIGURE S1** OECs were collected from healthy volunteers' whole blood samples spiked with voxelotor. A total of 105 OECs were used to determine the correlation between p20 (A), p50 (B), ∆p20 (C) and ∆p50 (D) compared with \[voxelotor\]/(Hct\*5 mM). Based upon the correlations, p20 (*R* ^2^ = 0.88) and Δp20 (*R* ^2^ = 0.87) are the optimal parameters to follow in a clinical setting where voxelotor target dosing is at 40% or below the Hb concentration. Equation of the line, correlation and *N* values for all four panels can be found in Supplemental Table S2.

**FIGURE S2** OECs were collected from healthy volunteers' whole blood samples spiked with voxelotor. A total of 145 OECs were used to test the robustness of the four parameters evaluated. The four panels show how predictive the model was of predicting the \[voxelotor\]~RBC~ to \[Hb\]~RBC~ ratio (also known as the %Hb occupancy). The robustness of the model based upon either p20 (A), p50 (B), ∆p20 (C) or ∆p50 (D) can be assessed. In addition, the direct relationship between percent Hb modification and %Hb occupancy can be obtained from the slope of the line. Based upon the *R* ^2^ values and the slope of the lines (found in Supplemental Table S2), it is clear that using p50 is not predictive of the %Hb occupancy.

**FIGURE S3** OECs were collected from SCD patients whole blood samples spiked with voxelotor. A toal of 132 OECs were used to determine the correlation between p20 (A), p50 (B), ∆p20 (C) and ∆p50 (D) compared to \[voxelotor\]/(Hct\*5 mM). Based upon the correlations, ∆p20 (*R* ^2^ = 0.78) is the optimal parameter to follow in a clinical setting when voxelotor target dosing is at 40% or below the Hb concentration. Equation of the line, correlation and *N* values for all four panels can be found in Supplemental Table S3. The greater variability in the SCD data is likely due to varying 2,3 DPG levels in SCD patient blood, and therefore using the delta values provides an internal reference.

**FIGURE S4** OECs were collected from SCD patients' whole blood samples spiked with voxelotor. A total of 101 OECs were used to test the robustness of the four parameters evaluated. The four panels show how predictive the four models were of predicting the \[voxelotor\]~RBC~ to \[Hb\]~RBC~ ratio (also known as the %Hb occupancy). The robustness of the model based upon p20 (A), p50 (B), ∆p20 (C) and ∆p50 (D) was assessed. In addition, the direct relationship between percent Hb modification and %Hb occupancy can be judged from the slope of the line. Based upon the slope of the lines (found in Supplemental Table S3), it is clear that both p50 and ∆p50 are not predictive of the %Hb occupancy.
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